NASDAQ: OPTHOptimi Health Corp Stock
$4.87-0.01 (-0.2%)
Updated Jul 6, 2026
OPTH Price
$4.87
Fair Value Price
N/A
Market Cap
$27.89M
52 Week Low
$4.00
52 Week High
$6.40
P/E
N/A
P/B
10.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.82
Operating Cash Flow
N/A
Beta
4.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OPTH Overview
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OPTH's potential to beat the market
- OPTH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
OPTH
RankedUnranked of 53
RankedUnranked of 53
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $174.10 | A | |
| $16.80 | A | |
| $39.99 | A |
Be the first to know about important OPTH news, forecast changes, insider trades & much more!
OPTH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OPTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OPTH is poor value based on its book value relative to its share price (10.88x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.59x)
P/B vs Industry Valuation
OPTH's short-term liabilities ($7.12M) exceed its short-term assets ($404.76k)
Short-term Liabilities Financials
OPTH's short-term assets ($404.76k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more OPTH due diligence checks available for Premium users.
Valuation
OPTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.88x
Industry
1.59x
OPTH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OPTH's financial health
Profit margin
Revenue
$72.1k
Net Income
-$1.2M
Profit Margin
-1,599.9%
Assets to liabilities
Assets
$9.8M
Liabilities
$7.2M
Debt to equity
2.82
OPTH's short-term liabilities ($7.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OPTH's short-term assets ($404.76k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OPTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$241.5k
Investing
-$8.2k
Financing
-$29.3k
OPTH vs Pharmaceutical Stocks
Optimi Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.